RxDoctor Payments Data

Douglas Zmolek, MD

Internal Medicine · Manlius, NYNPI 1477534667

Payments from drug & device makers

$2,611in general payments, 2019–2025

Across 158 payments — averaging $16.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$384
  • Pfizer$321
  • AbbVie$275
  • Astellas Pharma US Inc$190
  • Boehringer Ingelheim$180
  • Amgen$165
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$2,598100%
  • Education$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,611 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$85,932
Medicare patients
185
Services billed
1,194

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban102$115,513
JardianceEmpagliflozin43$64,111
OzempicSemaglutide39$57,429
XareltoRivaroxaban29$39,165
MounjaroTirzepatide25$35,841
JanuviaSitagliptin Phosphate19$26,858
RybelsusSemaglutide23$25,033
SynjardyEmpagliflozin/Metformin Hcl14$22,237
MyrbetriqMirabegron19$19,334
Repatha SureclickEvolocumab17$18,450
JanumetSitagliptin Phos/Metformin Hcl15$18,083
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$15,876
Janumet XrSitagliptin Phos/Metformin Hcl14$14,999
Repatha SyringeEvolocumab18$14,571
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr23$11,830

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$321$115,513102 claims
Boehringer IngelheimJardiance, Synjardy$180$86,34957 claims
Novo NordiskOzempic, Rybelsus$147$82,46262 claims
MerckJanuvia, Janumet, Janumet Xr$67$59,94148 claims
Johnson & JohnsonXarelto$134$39,16529 claims
Lilly USA, LLCMounjaro$87$35,84125 claims
GSKTrelegy Ellipta, Anoro Ellipta$384$27,70641 claims
Astellas Pharma US IncMyrbetriq$190$19,33419 claims
AbbVieSynthroid$275$3,62447 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Manlius

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →